Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Ted Bosworth

News

Noncardiac mortality is not increased by revascularization in a meta-analysis: New data refute recent study

Author:
Ted Bosworth
Publish date: May 30, 2023

Contrary to previous findings, no increased risk of noncardiac mortality was associated with revascularization in a meta-analysis of 18 trials.

  • Read More

News

ECMO signals benefit for cardiogenic shock after MI in halted trial

Author:
Ted Bosworth
Publish date: May 30, 2023

Although based on small numbers in a halted trial, ECMO was associated with reduced mortality for PCI patients in MI-related cardiogenic shock,...

  • Read More

News

Noninferior to DES, novel bioadaptable stent may improve target vessel physiology

Author:
Ted Bosworth
Publish date: May 22, 2023

By restoring blood vessel hemodynamics, a novel bioadaptable – as opposed to bioabsorbable – coronary stent might change long-term outcomes,...

  • Read More

News

Transcatheter tricuspid valve repair in real-world setting replicates trials

Author:
Ted Bosworth
Publish date: May 19, 2023

Two transcatheter tricuspid valve repair systems in the real world reflect safety and efficacy seen in trials.

  • Read More

News

Evidence of TAVR benefit extends to cardiogenic shock

Author:
Ted Bosworth
Publish date: May 18, 2023

Patients in cardiogenic shock should not be excluded from transcatheter aortic valve replacement, despite some early adverse event risk, new...

  • Read More

News

Redo-TAVR in U.S. database yields good news: Outcomes rival first intervention

Author:
Ted Bosworth
Publish date: May 17, 2023

A large transcatheter aortic valve transplant (TAVR) database shows a second procedure performs about as well as native TAVR.

  • Read More

News

Stroke scale cutoff might not be ideal guide for ordering CTA and detecting large vessel occlusions

Author:
Ted Bosworth
Publish date: May 5, 2023

If the goal is not to miss any LVOs, there is no NIHSS score below which these do not occur.

  • Read More

News

Teriflunomide delays MS symptoms in radiologically isolated syndrome

Author:
Ted Bosworth
Publish date: May 5, 2023

The data support the theory that treatment should begin early in patients with a high likelihood of developing symptomatic MS on the basis of...

  • Read More

News

Novel levodopa delivery system promises continuous dosing without surgery or pump

Author:
Ted Bosworth
Publish date: May 4, 2023

The experimental device is designed to deliver levodopa and carbidopa into the mouth through a micropump within a wearable retainer.

  • Read More

News

Machine learning can predict primary progressive MS progression

Author:
Ted Bosworth
Publish date: April 27, 2023

The model, which is clinically viable even as it is still evolving, predicts disability progression with an accuracy of approximately 70%.

  • Read More

News

Therapy to reverse muscle dystrophies shows promise

Author:
Ted Bosworth
Publish date: April 27, 2023

Interim study data showed rapid reductions in multiple biomarkers of muscle injury, reductions in anti-inflammatory markers, proteomic changes...

  • Read More

News

Phase 3 study of new levodopa/carbidopa delivery system meets all efficacy endpoints

Author:
Ted Bosworth
Publish date: April 25, 2023

The subcutaneous infusion system improved ON time without troublesome dyskinesias while improving symptoms according to ratings from both patients...

  • Read More

News

Explanation proposed for long-COVID symptoms in the CNS

Author:
Ted Bosworth
Publish date: April 24, 2023

In the case of persistent neurologic symptoms after COVID, antibodies produced for previously encountered coronaviruses rather than for SARS-CoV2...

  • Read More

News

JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial

Author:
Ted Bosworth
Publish date: March 29, 2023

The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...

  • Read More

News

New data forecast more oral PDE4 inhibitors for psoriasis

Author:
Ted Bosworth
Publish date: March 27, 2023

The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close